Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer

Diana Lüftner; Michael P Lux; Tanja N Fehm; Manfred Welslau; Volkmar Müller; Florian Schütz; Peter A Fasching; Wolfgang Janni; Christoph Thomssen; Isabell Witzel; Milena Beierlein; Erik Belleville; Michael Untch; Marc Thill; Nina Ditsch; Bahriye Aktas; Maggie Banys-Paluchowski; Cornelia Kolberg-Liedtke; Achim Wöckel; Hans-Christian Kolberg; Nadia Harbeck; Elmar Stickeler; Hans Tesch; Andreas D Hartkopf

doi:10.1055/a-2018-9184

Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer

Diana Lüftner, Michael P Lux, Tanja N Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Milena Beierlein, Erik Belleville, Michael Untch, Marc Thill, Nina Ditsch, Bahriye Aktas, Maggie Banys-Paluchowski, Cornelia Kolberg-Liedtke, Achim Wöckel, Hans-Christian KolbergNadia Harbeck, Elmar Stickeler, Hans Tesch, Andreas D Hartkopf

4 Citations (Scopus)

Abstract

Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody-drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody-drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.

Original language	English
Journal	Geburtshilfe und Frauenheilkunde
Volume	83
Issue number	03
Pages (from-to)	299-309
Number of pages	11
ISSN	0016-5751
DOIs	https://doi.org/10.1055/a-2018-9184
Publication status	Published - 03.2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Centers: University Cancer Center Schleswig-Holstein (UCCSH)
Research Area: Luebeck Integrated Oncology Network (LION)

DFG Research Classification Scheme

2.22-14 Hematology, Oncology
2.22-21 Gynaecology and Obstetrics

Access to Document

10.1055/a-2018-9184

Cite this

Lüftner, D., Lux, M. P., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., Beierlein, M., Belleville, E., Untch, M., Thill, M., Ditsch, N., Aktas, B., Banys-Paluchowski, M., Kolberg-Liedtke, C., Wöckel, A., ... Hartkopf, A. D. (2023). Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer. Geburtshilfe und Frauenheilkunde, 83(03), 299-309. https://doi.org/10.1055/a-2018-9184

@article{dd347688359a46f5a267ff783ada53cf,

title = "Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer",

abstract = "Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody-drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody-drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.",

author = "Diana L{\"u}ftner and Lux, \{Michael P\} and Fehm, \{Tanja N\} and Manfred Welslau and Volkmar M{\"u}ller and Florian Sch{\"u}tz and Fasching, \{Peter A\} and Wolfgang Janni and Christoph Thomssen and Isabell Witzel and Milena Beierlein and Erik Belleville and Michael Untch and Marc Thill and Nina Ditsch and Bahriye Aktas and Maggie Banys-Paluchowski and Cornelia Kolberg-Liedtke and Achim W{\"o}ckel and Hans-Christian Kolberg and Nadia Harbeck and Elmar Stickeler and Hans Tesch and Hartkopf, \{Andreas D\}",

note = "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ). Publisher Copyright: {\textcopyright} 2023 The Author(s).",

year = "2023",

month = mar,

doi = "10.1055/a-2018-9184",

language = "English",

volume = "83",

pages = "299--309",

journal = "Geburtshilfe und Frauenheilkunde",

issn = "0016-5751",

publisher = "Georg Thieme Verlag",

number = "03",

}

Lüftner, D, Lux, MP, Fehm, TN, Welslau, M, Müller, V, Schütz, F, Fasching, PA, Janni, W, Thomssen, C, Witzel, I, Beierlein, M, Belleville, E, Untch, M, Thill, M, Ditsch, N, Aktas, B, Banys-Paluchowski, M, Kolberg-Liedtke, C, Wöckel, A, Kolberg, H-C, Harbeck, N, Stickeler, E, Tesch, H & Hartkopf, AD 2023, 'Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer', Geburtshilfe und Frauenheilkunde, vol. 83, no. 03, pp. 299-309. https://doi.org/10.1055/a-2018-9184

TY - JOUR

T1 - Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer

AU - Lüftner, Diana

AU - Lux, Michael P

AU - Fehm, Tanja N

AU - Welslau, Manfred

AU - Müller, Volkmar

AU - Schütz, Florian

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Thomssen, Christoph

AU - Witzel, Isabell

AU - Beierlein, Milena

AU - Belleville, Erik

AU - Untch, Michael

AU - Thill, Marc

AU - Ditsch, Nina

AU - Aktas, Bahriye

AU - Banys-Paluchowski, Maggie

AU - Kolberg-Liedtke, Cornelia

AU - Wöckel, Achim

AU - Kolberg, Hans-Christian

AU - Harbeck, Nadia

AU - Stickeler, Elmar

AU - Tesch, Hans

AU - Hartkopf, Andreas D

N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ). Publisher Copyright: © 2023 The Author(s).

PY - 2023/3

Y1 - 2023/3

N2 - Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody-drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody-drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.

AB - Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody-drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody-drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.

UR - https://www.scopus.com/pages/publications/85150436628

UR - https://www.mendeley.com/catalogue/00014038-f4bf-3658-bae7-58ef56a37ad7/

U2 - 10.1055/a-2018-9184

DO - 10.1055/a-2018-9184

M3 - Scientific review articles

C2 - 36908287

SN - 0016-5751

VL - 83

SP - 299

EP - 309

JO - Geburtshilfe und Frauenheilkunde

JF - Geburtshilfe und Frauenheilkunde

IS - 03

ER -

Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer

Abstract

UN SDGs

Research Areas and Centers

DFG Research Classification Scheme

Access to Document

Other files and links

Fingerprint

Cite this